Faculty: Julie Margenthaler, MD and Sarah McLaughlin, MD
Based on the SSO 2019 Great Debate, this webinar will present data and compare and contrast the benefits and limitations of upfront surgery and neoadjuvant therapy for resectable HER2+/TNBC.
You may find this activity in the Breast Disease section in the ExpertED@SSO catalog.
This activity is partially supported by an independent educational grant from Genentech.